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Abstract
Background: Previous studies indicate that the introduction of high-sensitivity troponin T (HsTnT) as a diagnostic
tool for chest pain patients in the emergency department (ED) creates a high rate of false-positive tests. In the
present study, we aimed to evaluate if the diagnostic performance of HsTnT for acute coronary syndrome (ACS) up
to 3–4 h after presentation in elderly patients can be improved.
Methods: A total of 477 consecutive patients≥ 75 years, admitted to in-hospital care for chest pain suspicious of ACS,
were retrospectively included. HsTnT values at presentation (0 h) and at 3–4 h were analysed. Receiver operating
characteristic (ROC) curves were created for absolute and relative changes from 0 to 3–4 h. ACS, non-elective
percutaneous coronary intervention, coronary artery bypass grafting and death of all causes were recorded for all
patients during a follow-up of 60 days. Sensitivity, specificity, negative predictive value (NPV) and positive predictive
value (PPV) were analysed for different HsTnT cut-off values at 0 and 3–4 h and for the combination of a HsTnT at
presentation and an absolute change from 0 to 3–4 h.
Results: Twenty-seven percent of the patients had ACS and 21 % acute myocardial infarction (AMI) during the hospital
stay. The standard cut-off 14 ng/L gave sensitivity and NPV for ACS of 88 and 90 % at 3–4 h. Specificity and PPV was 38
and 32 % respectively. Analysing for non-ST elevation myocardial infarction (NSTEMI) alone gave a sensitivity and NPV
of 100 % but did not improve specificity and PPV. The area under the ROC-curve was larger for absolute than relative
HsTnT changes from 0 to 3–4 h. A combination of HsTnT at presentation > 30 ng/L and/or a change > 5 ng/L up to
3–4 h gave a 63 % specificity and a PPV of 46 %, a 99 % sensitivity and a NPV of 99 % for NSTEMI.
Conclusion: Our study indicates that HsTnT can neither exclude nor confirm ACS within 3–4 h from presentation in
patients≥ 75 years. NSTEMI can be excluded with HsTnT within 3–4 h, but HsTnT cannot be used to rule in NSTEMI
during the first 3–4 h, not even by using a combination of the initial HsTnT result and the change from 0 to 3–4 h.
With combined criteria, the majority of the positive tests were still false positive. Our results indicate that in
patients > 75 years, HsTnT should be used primarily as an early rule-out tool for AMI.
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Background
The cornerstones in the evaluation of emergency
department (ED) patients with possible acute coronary
syndrome (ACS), including acute myocardial infarction
(AMI), are the ECG, the symptom history, and blood
markers of myocardial necrosis such as troponin. With
the introduction of high-sensitivity assays, extremely low
concentrations of cardiac troponins in the blood can be
measured with excellent precision [1]. However, in-
creased analytic sensitivity of troponin assays not only
increases detection of AMI [2, 3], but also of the many
other conditions with elevated troponin levels [4, 5].
These conditions, e.g. pulmonary embolism, heart
failure, tachycardia and renal failure are more common
in elderly patients.
In the latest European guidelines [6], the AMI diagno-
sis requires a rise or fall in blood troponin with at least
one value above the 99th percentile [7]. It is also stated
that ACS may be excluded with a rapid 3 h high-
sensitivity troponin sampling protocol.
With the high-sensitivity troponin T (HsTnT) assay
the level of the 99th percentile is as low as 14 ng/L. Pre-
vious studies indicate that this cut-off creates a high rate
of false-positive tests [8], and concerns have been raised
that this decreases the diagnostic value of HsTnT for
AMI in elderly patients [8–13].
In the present study, we aimed to evaluate if the diag-
nostic performance of HsTnT for ACS up to 3–4 h after
presentation in elderly patients could be improved.
Methods
Study site
The Skåne University Hospital in Lund serves as the pri-
mary hospital for approximately 300 000 inhabitants.
The hospital has a cardiac intensive care unit with 19
beds and an observation unit with ECG monitoring at
20 beds. Percutaneous coronary intervention (PCI) and
coronary artery bypass grafting (CABG) are available
24 h a day. Some 65 000 patients present to the ED per
year, and approximately 5500 of these present with acute
chest pain. There is no standardized diagnostic protocol
for patients with suspected ACS, and no dedicated chest
pain unit. A prehospital ECG system is in operation,
with ambulance ECGs sent to a cardiologist on call. If
an ST elevation myocardial infarction (STEMI) is identi-
fied, the patient is transported directly to the angiog-
raphy laboratory, bypassing the ED.
Inclusion of patients
All patients ≥ 75 years with chest pain suspicious of
ACS, as identified and noted in the patient records by
the responsible ED physician, were retrospectively in-
cluded in the study database if they were admitted from
the ED to the cardiac intensive care unit or the medical
observation unit during the period of February to April
2010, March to July 2011 and October 2011 to March
2012. The study period was divided into three for prac-
tical reasons and due to the limitations in the hospital’s
administrative routines. Patients identified as very low
risk by the responsible ED physician were directly dis-
charged home from the ED and were not included in
the study. We also excluded patients with STEMI,
cardiac arrest at the ED or living outside the region. The
study was approved by the the Regional Ethical Review
Board in Lund (http://www.epn.se), registry number
2010/429. The Regional Ethics Review Board did not re-
quest written informed consent.
Clinical assessment
All patients underwent routine assessment in the ED
including physical examination, 12-lead ECG and labora-
tory analyses including HsTnT. After admission to the
observation or the cardiac intensive care unit, all in-
cluded patients were subjected to continuous ECG
monitoring, pulse oxymetry and non-invasive blood
pressure measurements. Blood samples for HsTnT ana-
lysis were collected at presentation (0 h) and thereafter
at the discretion of the attending physician, but mainly
at 3–4 h and 6–7 h from presentation according to the
ESC guidelines [6].
High sensitivity troponin T assay
The HsTnT analyses were performed with the use of the
Elecsys 2010 system (Roche Diagnostics) with a limit of
detection of 2 ng/l, a 99th-percentile cut-off point of
14 ng/l, and a coefficient of variation of less than 10 at
13 ng/l.
Recording of patient diagnoses and endpoints
For patients admitted to in-hospital care, the final
discharge diagnosis (including the ICD10 code) based on
clinical data from the entire hospital stay was retrieved
from the discharge summary written by the ward
physician and reviewed for quality by the responsible
specialist ward physician (cardiologist and/or internal
medicine specialist). The diagnostic criteria for ACS, AMI
or UA used at the hospital during the study were those
recommended by the European Society of Cardiology, the
American College of Cardiology and the American Heart
Association [7]. HsTnT values above 14 ng/L were con-
sidered indicative of ACS. In addition, all diagnoses and
ECGs were reviewed by two of the authors (CB, specialist
in cardiology and internal medicine, and KLF, specialist in
internal and emergency medicine) who finally decided
each diagnose in consensus using all available clinical data
for each patient. In patients with an HsTnT > 14 ng/L, a
20 % rise or fall was considered sufficient for an AMI
diagnosis together with a clinical course suggestive of
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ACS, i.e. typical pain location and duration, ECG changes
and no other obvious cause of the chest pain. [14]. The
UA diagnosis was considered correct when a patient had
an HsTnT that was normal or without dynamic changes,
together with deterioration of previous stable angina,
typical chest pain at rest, or had a positive cardiac stress
test or significant stenosis on coronary angiography. A
type 2 AMI was deemed by the reviewers to be present
when there was ischemic myocardial damage due to
imbalance between oxygen demand and supply, as in e.g.
tachycardia or hypoxemia. Since we focused on the diag-
nostic value of HsTnT for downstream ACS management,
these patients were considered as non-ACS cases in all
analyses except for the group called “all AMI”, see Table 2.
The endpoints analysed were ACS, NSTEMI, all AMI
(NSTEMI and Type 2 AMI) and MACE (NSTEMI, non-
elective PCI, non-elective CABG and death of all causes
within 2 months, including the initial stay).
Statistical analysis
Patient characteristics
Continuous variables are presented as medians (with
inter-quartile range) and were compared with the Mann–
Whitney test. Categorical variables were compared with
the Pearson Chi-square test.
Assessment of diagnostic performance
Sensitivity, specificity, negative predictive value (NPV)
and positive predictive value (PPV) were analysed for
HsTnT cut-off values at 3–4 h and for the combination
of a cut-off value at presentation and an absolute change
from 0 to 3–4 h. The different cut-off values were pre-
specified and based on previous studies [11, 12]. Sensi-
tivity and specificity with 95 % confidence intervals were
calculated. A sensitivity of ≥ 98 % was considered as a
clinically acceptable rule out level [15].
Receiver operating characteristic (ROC) curves were cre-
ated and the areas under the curves (AUROC) compared
for absolute and relative HsTnT changes (in percent) from
presentation to 3–4 h. IBM SPSS Statistics 18 (New York,
USA) was used for statistical analyses, and a p < 0.05 was
regarded as statistically significant.
For calculations of 95 % confidence intervals (CI) Vassar-
Stats clinical calculator (Vassar College, Poughkeepsie,
NY: http://faculty.vassar.edu/lowry/clin1.html) was used.
Results
Patient outcomes and characteristics
A total of 477 patients with suspected ACS were in-
cluded in the study. As seen in Table 1, 127 patients
(27 %) had a final discharge diagnosis of ACS and of
these, 28 had UA. Nineteen of the UA patients (68 %)
were diagnosed after coronary angiography. Twenty-five
patients (5 %) were considered to have type 2 AMI, and
these are included in the non-ACS group. In total, 143
patients (30 %) had a MACE within 2 months. Twelve
patients died after the initial hospital stay and six
patients were diagnosed with ACS after the initial stay
but within 2 months. None of the patients diagnosed
with ACS after the initial stay died. The causes of death
were not registered.
Only 49 of the patients with ACS (38 %) presented
with ECG changes not known to be old. As seen in
Table 1, there were no significant differences in prior
cardiovascular disease between patients with and with-
out ACS. Male sex was significantly more common and
warfarin treatment significantly less common in the ACS
group. Average age was similar in patients with and
without ACS, but GRACE score was significantly higher
in the group with ACS. HsTnT levels and the number of
HsTnT positive (>14 ng/L) patients at ED presentation
were significantly higher in patients with ACS than in
the non-ACS group.
HsTnT analysis at presentation and at 3–4 h
With the cut-off 14 ng/L, the sensitivity for NSTEMI at
presentation was 91 % (CI 95 % 83–91) with a specificity
of 43 % (CI 95 % 38–48). Increasing the cut-off values at
presentation resulted in even lower levels of sensitivity
(data not shown).
Three hundred and twelve patients (65 %) had an
hsTnT result at 3–4 h. In Table 2, panel a, it can be seen
that with the cut-off 14 ng/L, the sensitivity for ACS was
88 % at 3–4 h, with a specificity of 38 %. Analysing for
NSTEMI alone (panel b) gave a sensitivity and NPV of
100 % but did not improve specificity and PPV. When
diagnostic performance for all AMI (NSTEMI and Type
2 AMI) were analysed (panel c), sensitivity and NPV
reached 100 % but specificity remained low at 41 %. The
sensitivity and specificity for MACE at 2 months (panel d)
were 91 and 39 %. Using the cut-offs 20 and 30 ng/L
decreased sensitivity and increased specificity for all
endpoints.
HsTnT changes
For the diagnosis of AMI, areas under the ROC curves
for relative and absolute HsTnT changes were analysed.
As shown in Fig. 1, AUROC was larger for absolute than
for relative HsTnT changes from 0 to 3–4 h.
Single HsTnT analyses combined with HsTnT changes
In an attempt to improve specificity and PPV for
NSTEMI, a single HsTnT value at presentation was
combined with the absolute HsTnT change from 0 to
3–4 h, and the results are shown in Table 3. A com-
bination of HsTnT at presentation > 30 ng/L and/or a
change > 5 ng/L gave a 63 % specificity and a PPV of 46 %,
a 99 % sensitivity and a NPV of 99 % for NSTEMI. On the
Borna et al. BMC Emergency Medicine  (2016) 16:1 Page 3 of 9
assumption that 98 % sensitivity is acceptable in routine
care, these criteria would allow NSTEMI to be ruled out
at 3–4 h in 47 % of the patients.
Increasing the cut-offs for the initial HsTnT or the
absolute change decreased the sensitivity to less than
98 %. A combination of the HsTnT result at 3–4 h with
the change from 0 to 3–4 h did not improve these
results (data not shown).
Patients without ACS
Of 477 study patients, 350 (73 %) did not have ACS dur-
ing the index visit. HsTnT at presentation was patho-
logical in 197 (58 %) of these patients (Table 1). Table 4
shows the discharge diagnoses for all patients. As can be
seen, an elevated HsTnT at the ED was very common in
patients with pneumonia, pulmonary embolism and
heart failure. All patients with type 2 AMI had clinical
Table 1 Characteristics and outcomes for study patients
All ACS Non-ACS p value
(n = 477) (n = 127) (n = 350) (ACS vs non-ACS)
Age, median (IQR) years 82 (77–85) 82 (78–85) 81 (68–88) 0.38
Male sex 253 (53) 77 (61) 175 (50) 0.04
Medical history Hypertension 279 (59) 79 (62) 200 (57) 0.33
Hyperlipidemia and/or use of statins 230 (48) 63 (50) 167 (48) 0.72
Diabetes 116 (24) 38 (30) 78 (22) 0.09
CAD 281 (59) 74 (58) 207 (59) 0.86
Prior PCI 130 (27) 34 (27) 96 (27) 0.89
Prior CABG 94 (20) 23 (18) 71 (20) 0.60
Stroke 86 (18) 24 (19) 62 (18) 0.77
CHF 90 (19) 27 (21) 63 (18) 0.40
Smoking status Current 32 (6.7) 10 (8.4) 21 (6.1) 0.70
Current medication Warfarin 87 (18) 11 (9) 76 (22) <0.01
Findings on presentation Heart rate (beats/min) 77 80 76 0.08
Systolic blood pressure (mmHg) 150 150 147 0.20
Diastolic blood pressure (mmHg) 80 80 80 0.04
ECG ST depression 53 (11) 32 (25) 21 (6) <0.01
ST elevation 13 (3) 5 (4) 8 (2) 0.33
T-Wave inversion 21 (4) 9 (7) 12 (3) 0.09
Left bundle branch block 7 (1) 3 (2) 4 (1) 0.33
Right bundle branch block 3 (1) 0 3 (1) 0.30
Non interpretable ECG (pacemaker) 44 (9) 14 (11) 30 (9) 0.41
Laboratory tests CRP (mg/L) 2.9 2.8 2.9 0.73
Creatinine (μmol/L) 94 99 92 0.04
Cholesterol (mmol/L) 4.2 4.2 4.1 0.69
Troponin at presentation median (IQR) 20 (11–37) 37 (19–116) 17 (8–28) <0.01
Troponin positive at presentation 297 (63) 100 (81) 197 (58) <0.01
Abs diff T0T3 2 (1–7) 18 (4–67) 2 (0–4) <0.01
GRACE score median (IQR) 142 (125–164) 150 (128–177) 140 (124–156) 0.01
In-hospital outcome Coronary angiography 104 (22) 83 (65) 21 (6) <0.01
PCI 39 (8) 39 (8) 0 <0.01
CABG 27 (6) 27 (6) 0 <0.01
Death 13 (3) 7 (6) 6 (2) 0.02
Data are given as n (%) or median (interquartile range [IQR]). CAD coronary artery disease, CHF congestive heart failure, ACS acute coronary syndrome,
PCI percutaneous coronary intervention, CABG coronary artery bypass grafting, GRACE Global Registry of Acute Coronary Events, Abs diff T0T3 absolute
change in HsTnT from admission to 3 h. Standard clinical definitions of hypertension, Hyperlipidemia, Diabetes, CAD, stroke and CHF were used
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conditions that made in-hospital care necessary regard-
less of the HsTnT value.
Discussion
In the present study in patients > 75 years, there were
three main findings. First, the rapid 3 h HsTnT protocol
suggested by the latest European guidelines cannot be
used to rule in or rule out ACS during the hospital stay
or MACE within two months. Second, a single HsTnT at
3–4 h from patient presentation can rule out NSTEMI.
Third, HsTnT cannot be used to rule in NSTEMI during
the initial 3–4 h using either standard or adjusted cut-
offs, or a combination of the initial HsTnT result and
the change from 0 to 3–4 h.
In patients with possible ACS, the main diagnostic
methods in the ED are symptom history, ECG and blood
tests such as HsTnT. The chest pain history was not re-
corded in our study, but it is well known that elderly
ACS patients often have atypical symptoms such as
shortness of breath or fatigue, which makes the diag-
nosis difficult [16]. The diagnostic yield of the ECG was
low in our patient population, since the ECG was nor-
mal or unchanged from a previous ECG in 62 % of the
ACS patients. In view of this, it seems important to
optimize the diagnostic performance of HsTnT in
elderly patients in order to avoid unnecessary admission
to in-hospital care, over-investigation and over-treatment
with anticoagulant and antiplatelet drugs for ACS,
especially since elderly patients have more comorbidity
than younger patients and are at a higher risk of adverse
drug effects.
The European Society of Cardiology (ESC) state that
non-ST-elevation acute coronary syndromes can be ex-
cluded with a rapid 3 h HsTn sampling protocol [17]. We
found that this protocol, using the standard cut-off 14 ng/L,
had a sensitivity for ACS at 3–4 h of less than 90 % with a
NPV of 90 %. Our conclusion is that the ESC’s rapid HsTn
sampling protocol cannot rule out ACS within 3–4 h after
presentation. These results are in accordance with our
previous finding in patients of all ages that HsTnT cannot
rule out ACS up to 6–7 h after presentation [8], and with
the results of the meta-analysis by Sethi et al. [18].
Table 2 Diagnostic performance for ACS (a), NSTEMI (b), all AMI (c) and MACE after 2 months (d) of HsTnT analysed 3–4 h
a) ACS prediction at 3–4 h Sensitivity Specificity NPV PPV
n = 77 (95 % CI) (95 % CI) (95 % CI) (95 % CI)
HsTnT
>14 88 (78–94) 38 (32–44) 90 (83–95) 32 (26–35)
>20 81 (70–88) 58 (52–65) 90 (84–90) 39 (31–47)
>30 77 (65–85) 75 (69–80) 91 (86–94) 50 (41–59)
b) NSTEMI prediction at 3–4 h
n = 61
HsTnT
>14 100 (93–100) 39 (33–45) 100 (95–100) 28 (22–35)
>20 93 (83–98) 59 (53–65) 97 (93–99 36 (28–44)
>30 90 (79–96) 75 (69–80) 97 (93–99) 47 (37–56)
c) All AMI prediction at 3–4 h
n = 81
HsTnT
>14 100 (94–100) 41 (35–48) 100 (95–100) 36 (32–43)
>20 94 (85–98) 63 (56–69) 97 (92–99) 45 (37–53)
>30 90 (80–95) 80 (73–84) 96 (92–98) 58 (49–67)
d) MACE prediction at 3–4 h
n = 86
HsTnT
>14 91 (83–96) 39 (33–46) 93 (85–97) 35 (29–42)
>20 83 (73–90) 60 (54–66) 91 (85–95) 42 (35–51)
>30 77 (66–85) 77 (70–81) 90 (85–94) 53 (44–63)
TnT high-sensitivity troponin T, AMI acute myocardial infarction, NSTEMI non-ST-elevation myocardial infarction
All AMI includes NSTEMI and Type 2 AMI. MACE, NSTEMI, non-elective PCI, non-elective CABG and death within 2 months
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Fig. 1 ROC curves for AMI prediction of absolute and relative HsTnT changes from presentation to 3–4 h. Areas under the curves: 0.94 (95 % confidence
interval 0.899–0.972) for absolute HsTnT change and 0.82 (95 % confidence interval 0.759–0.885) for relative change









HsTnT at presentation >14
and/or abs Δ to 3–4 h >5 99 (93–100) 30 (25–36) 99 (94–100) 30 (25–35)
>7 98 (92–100) 32 (27–38) 98 (92–100) 30 (25–36)
>9 96 (89–99) 32 (27–38) 96 (90–99) 30 (25–35)
HsTnT at presentation >20
and/or abs Δ to 3–4 h >5 99 (93–100) 46 (41–52) 99 (96–100) 36 (30–43)
>7 98 (92–100) 49 (43–54) 99 (95–100) 37 (31–44)
>9 96 (89–99) 49 (43–54) 97 (93–99) 37 (31–43)
HsTnT at presentation >30
and/or abs Δ to 3–4 h >5 99 (93–100) 63 (57–68) 99 (96–100) 46 (40–54)
>7 97 (90–99) 66 (60–72) 98 (95–100) 48 (41–56)
>9 94 (87–98) 67 (61–72) 97 (94–99) 48 (41–56)
HsTnT at presentation >40
and/or abs Δ to 3–4 h >5 95 (88–98) 70 (64–76) 98 (94–99) 51 (43–59)
>7 91 (82–96) 75 (70–80) 96 (92–98) 54 (46–62)
>9 88 (80–94) 76 (70–81) 95 (91–98) 54 (46–63)
TnT high-sensitivity troponin T, NSTEMI non-ST-elevation myocardial infarction, abs Δ to 3–4 h, absolute change TnT from admission to 3–4 h. A sensitivity of ≥ 98 % is
considered acceptable for rule out
Best diagnostic performance is marked with grey
Borna et al. BMC Emergency Medicine  (2016) 16:1 Page 6 of 9
However, in our patients > 75 years we observed that a
single HsTnT at 3–4 h was an excellent way to exclude
NSTEMI; the sensitivity was 100 %. This finding has
been well described in previous studies [8, 19]. After
NSTEMI has been excluded however, the question re-
mains whether the patient can be safely discharged from
the ED or whether he or she should be further assessed
for UA. Since UA is a difficult and often ambiguous
diagnosis, especially in elderly patients who often do not
undergo coronary angiography due to the inherent risks,
we also evaluated the diagnostic performance of HsTnT
for MACE within 2 months. MACE included more
robust events such as NSTEMI, non-elective PCI or
CABG and death of all causes. Sensitivity and NPV for
MACE were similar to those for ACS alone, indicating
that excluding NSTEMI at the ED is not sufficient for
optimal care, even if the 60-day follow-up in this study
was quite generous.
This study indicates that HsTnT cannot be used to
rule in NSTEMI during the initial 3–4 h using either
standard or adjusted cut-offs, or a combination of the
initial HsTnT result and the change from 0 to 3–4 h.
Using the standard cut off 14 ng/L, the ability of a
single HsTnT at 3–4 h to rule in both NSTEMI and all
AMI (NSTEMI and Type 2 AMI) was poor, since speci-
ficities and PPVs were below 50 %. This low specificity
of HsTnT for AMI (and ACS) confirms previous results
by Borna [8], Bahrmann [9] and Olivieri et al. [20], and
is also well described in the meta-analysis by Sethi et al.
[18]. Conditions associated with elevated troponin levels
are frequent in the elderly, and in our study the initial
HsTnT was > 14 ng/L in all patients with pneumonia or
pulmonary embolism, and in almost all patients with
heart failure or atrial fibrillation (Table 4). Taken to-
gether with the considerable biological variation in the
HsTnT level over time [21], this can explain why the
diagnostic yield of the HsTnT change during the initial
hours for rule-in was limited in patients ≥ 75 years.
Another possible cause is that some of the patients were
so called “late presenters” and arrived to the ED with an
established infarction. The time of chest pain onset was
not registered in the present study.
Increasing the cut off values for single HsTnT tests
(Table 2) improved specificity but at a clinically accept-
able sensitivity of ≥ 98 %, PPV did not exceed 50 %.
HsTnT as a single analysis in the elderly thus has simi-
larities with the d-dimer test where a positive result is
not useful to rule in thrombosis due to its low specificity
and PPV [22].
In order to improve PPV and reduce the number of
false positive tests, we evaluated a combination of a
higher HsTnT cut-off at presentation and a low HsTnT
change up to 3–4 h. In this way, patients without AMI
but with an elevated baseline troponin level were not
classified as AMI, while AMI patients with low baseline
HsTnT values could still be identified by the HsTnT
change. Like previous studies we found that absolute
change in HsTnT was diagnostically superior to relative
change [23, 24]. Our combined criteria considerably
improved specificity and PPV, and with HsTnT at pres-
entation > 30 ng/L and/or a change > 5 ng/L, NSTEMI
could be ruled out within the first 3–4 h in 47 % of
unselected ED patients > 75 years.
Combinations of adjusted cut-off values at presenta-
tion and HsTnT changes over time have been evaluated
in two previous studies. Reichlin et al. [25] reported that
a 12 ng/L cut-off at presentation and/or change in
HsTnT of < 3 ng/L within the first hour ruled out AMI
in 60 % of chest pain patients of all ages with a sen-
sitivity and NPV of 100 %. Similarly, Bahrmann et al. [19]
combined an HsTnT < 23 ng/L at presentation and/or a
change < 3 ng/L within the first 3 h and could rule out
NSTEMI in one-third of unselected ED patients older
than 70 years.
Despite the improved specificity and PPV with our
combined criteria, it seems unlikely that they will
improve clinical care. With combined criteria, PPV still
did not reach more than 46 % when aiming at a
Table 4 Discharge diagnoses (ICD10, all patients)
ICD10 Number Percent % hsTnT > 14 at presentation % hsTnT > 30 at presentation
Ischaemic heart disease I20-I25 161 34 74 51
Chest pain R07 135 28 42 15
Atrial fibrillation and flutter I48 36 8 78 19
Heart failure I50 14 3 86 43
Pneumonia J18 11 2 100 46
Non specified disease Z00 9 2 67 33
Soft tissue disorder M79 7 2 42 14
Pulmonary embolism I26 6 1 100 33
Gastro-esophageal reflux disease K21 + K29 6 1 17 17
Other diagnoses - 92 19 - -
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sensitivity of ≥ 98 %. More than half of our elderly
patients with positive criteria did thus not have NSTEMI.
Additional information and observation after 3–4 h will
then be needed to make an NSTEMI diagnosis. Such a
rule in process could last for many hours or even days,
since the diagnosis will then depend on dynamic HsTnT
changes during the most likely “non-dynamic” phase of
troponin release from the infarcted myocardium [26].
Perhaps we will soon be ready to accept that it will often
be impossible to assign a working diagnosis of AMI using
only troponin as Rains et al. state in their review on
biomarkers of AMI in the elderly [27].
Limitations
This retrospective study was performed at one university
hospital only and all patients were admitted to wards
with capacity for close monitoring. Only patients who
were hospitalized following admission from the ED were
included. The results are not necessarily generalizable to
other patient populations, and need to be confirmed in a
prospective study.
As in many other studies on the diagnostic value of
troponin, incorporation bias was a substantial weakness
in our study. Although the discharge diagnoses were
based on clinical information from the entire hospital
stay, including HsTnT testing after 3–4 h, the HsTnT
results in this study were part of the information used to
make the discharge diagnosis. In addition, the review of
the discharge diagnoses was not independent, but per-
formed by the authors.
Another limitation in the interpretation of the results
is the lack of a gold standard. There is no clear defin-
ition on what dynamic changes of HsTnT are necessary
for the diagnosis of AMI. Further, consensus is lacking
regarding the diagnostic criteria for UA. Although many
were based on coronary angiography, the UA diagnoses
in this study may therefore not be entirely reproducible.
In the present paper, patients who were deemed to
have type 2 AMI were analyzed in the non-ACS group.
It could be argued that type 2 AMI diagnoses should be
included in the ACS group, but as it stands, troponin is
primarily used to identify patients with acute coronary
disease. A type 2 AMI diagnosis can be difficult to estab-
lish, especially in the absence of a coronary angiography,
but these diagnoses were based on consensus among the
2 reviewers and on evidence of little or no coronary
disease, e.g. previous stress tests. The type 2 AMI
diagnoses should therefore be reasonably correct.
Conclusion
Our study indicates that in patients ≥ 75 years, HsTnT
can neither exclude nor confirm ACS within 3–4 h of
presentation, but that a single HsTnT at 3–4 h can
exclude NSTEMI. In contrast, HsTnT cannot be used to
rule in NSTEMI during the first 3–4 h, not even by
using a combination of the initial HsTnT and/or the
change up to 3–4 h. With combined criteria, the majority
of the positive tests were still false positive. HsTnT in the
elderly is thus similar to the d-dimer test, where a positive
result cannot rule in venous thrombo-embolism. Our
results indicate that in patients > 75 years, HsTnT should
be used primarily as an early rule-out tool for AMI.
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